Dihexa Chemistry: The Angiotensin IV Analog That Potentiates the HGF/c-Met System

Dihexa is one of the more instructive small molecules in peptide research. It began as a blood-pressure peptide and, after some deliberate chemical surgery, ended up as a potent modulator of a growth-factor system in the brain. Everything discussed here concerns compounds sold for research use only — nothing below is a claim about human use. The interest is in the chemistry, and in what cell-culture and animal-model studies have actually reported. If you're researching this compound, its structure is the fastest route into why the research community keeps looking at it.

Below, we walk through the dihexa peptide structure, trace its origin in angiotensin IV, follow the structure-activity path that made it metabolically stable, and look at how published work describes its action on the HGF/c-Met system. We finish with a contrasting analog, norleual, that shows how a small structural edit can flip a molecule's behavior outright.

What Dihexa Is: Nomenclature and the Molecular Formula

In plain terms, dihexa is a small, chemically stabilized peptide-like molecule carrying the developmental code PNB-0408. Its working chemical name is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and its molecular formula is C27H44N4O5, with a molar mass of about 504.67 g/mol.

The structure reads most easily in three pieces. One end carries a six-carbon hexanoyl acyl chain. That connects to a tyrosine residue, then an isoleucine residue. The molecule then terminates in a six-carbon aminohexanoic amide linker. So instead of a conventional string of amino acids with free ends, dihexa is a capped, hydrophobic construct — and those caps turn out to be the whole point.

One framing note matters here. Research-grade dihexa is not equivalent to any FDA-approved pharmaceutical. A phosphate pro-drug of the molecule, fosgonimeton, is the entity that has advanced into clinical study for neurodegenerative research questions. The research-grade material and the investigational drug are separate things, and this article is about the former.

From Angiotensin IV to Dihexa: the Structure-Activity Path

The short version of this section: dihexa exists because angiotensin IV had the right activity but the wrong pharmacokinetics, so chemists rebuilt it to fix that.

The Nle-Tyr-Ile procognitive core

Angiotensin IV (AngIV) is a fragment of the angiotensin peptide family. Structure-activity work found that the information behind its cognition-relevant, synapse-building activity sits in just three N-terminal residues: norleucine, tyrosine, and isoleucine (Nle-Tyr-Ile). That mattered, because it meant researchers could protect a minimal three-residue scaffold instead of the whole peptide.

Stability was the sticking point. Nle1-AngIV had a serum half-life under two minutes — chewed apart almost immediately by aminopeptidases. A molecule that disappears that fast is hard to study in any systematic way.

Engineering for metabolic stability

So researchers screened a series of N-terminal modifications, and protecting that end of the molecule bought the most stability. Dihexa pushed the idea past simple protection. It removed the N-terminal amine entirely, replaced norleucine with a hexanoyl group, and added the C-terminal aminohexanoic amide linker. The payoff: more hydrophobicity, the loss of a critical hydrogen-bond site, and a serum half-life of roughly 335 minutes — a two-orders-of-magnitude jump over the parent peptide.

Hanging a lipid-like chain off a peptide to buy stability is a recurring trick, and we cover the general version in our explainer on attaching a fatty acyl chain to extend half-life. In the reported studies, the redesigned molecule was orally bioavailable, barely touched by liver metabolism, and able to cross the blood-brain barrier — all pharmacokinetic properties observed in research, not use recommendations.

The HGF/c-Met System and Why Researchers Care

To understand what dihexa does, you first need the system it acts on. HGF — hepatocyte growth factor — is a signaling protein. c-Met is its receptor, a receptor tyrosine kinase. When HGF engages c-Met, it kicks off signaling that research links to cell survival, tissue organization, and — the reason dihexa is studied — neuronal development and synaptic plasticity.

This pathway is notoriously hard to engage head-on. Native HGF has a serum half-life of only about 3.8 minutes and crosses the blood-brain barrier poorly. That combination is precisely why a small, stable, brain-penetrant molecule capable of influencing the same system caught the eye of synaptogenic and neurotrophic researchers.

There's a further reason the details matter: c-Met is also a known oncogene. That makes the difference between potentiating existing signaling and directly switching the receptor on more than an academic nicety — it sits at the center of how researchers reason about the molecule.

How Dihexa Potentiates the HGF/c-Met System

Binding and allosteric potentiation

In cell-culture work, dihexa binds HGF with a Kd of about 65 pM — an extremely tight interaction. What's telling is that it seems to potentiate HGF's activity at c-Met rather than agonizing the receptor directly. Put another way, it behaves more like allosteric rather than orthosteric modulation: it doesn't sit in the receptor's primary site and flip the switch itself, but amplifies what the natural ligand is already doing.

Synergy in cell culture

Synergy is the clearest fingerprint of that mechanism. When researchers combined subthreshold concentrations of HGF with subthreshold concentrations of dihexa, they saw maximal c-Met phosphorylation and a leftward shift of the HGF concentration-response curve — synergy, not simple addition. In kidney-cell scattering assays and hippocampal spine-formation assays, the combined subthreshold treatment produced spine densities on par with full-agonist concentrations of HGF used alone.

Confirming the pathway is required

How do researchers know the effect really runs through HGF/c-Met and not some side route? They blocked it. The HGF antagonist Hinge (peptide sequence KDYIRN) and c-Met knockdown via shRNA both abolished the synapse-building effect. In a separate zebrafish hair-cell model, dihexa was shown to bind and dimerize HGF into a functional ligand, and the dimerization-blocking antagonist 6-AH completely removed dihexa's protective activity. Remove the system, and the effect goes with it — the signature of a genuinely pathway-dependent action.

Same Scaffold, Opposite Directions: Norleual vs Dihexa

One of the neater lessons in this chemistry is that the very same angiotensin IV-analog scaffold can be tuned to inhibit the HGF/c-Met system rather than potentiate it.

The inhibitor is norleual. It carries a modified (reduced) peptide bond at the 3-4 position, which loosens the molecule up and lets it fold into shapes that mimic the "hinge" region of HGF. That hinge connects HGF's N-terminal and first kringle domains and helps mediate the interaction with c-Met. By impersonating it, norleual competitively blocks HGF from binding c-Met, with an IC50 around 3 pM — which, in that assay, makes it roughly ten-fold more potent than HGF itself.

The takeaway is a clean structure-activity story. A small change to one shared scaffold — a reduced peptide bond in one place, a hexanoyl cap in another — flips the direction of activity from potentiation (dihexa) to inhibition (norleual). That's exactly the kind of result that makes medicinal chemists study a molecular framework closely.

Frequently Asked Questions

What is dihexa's chemical structure?

Dihexa (developmental code PNB-0408) is the synthetic oligopeptide N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, with molecular formula C27H44N4O5 and a molar mass of about 504.67 g/mol. Structurally it links a six-carbon hexanoyl chain to tyrosine and isoleucine residues, ending in a six-carbon aminohexanoic amide — a design derived from the angiotensin IV scaffold.

How is dihexa related to angiotensin IV?

Dihexa is an engineered analog of angiotensin IV (AngIV). Research identified that the cognition-relevant information in AngIV resides in its three N-terminal residues, norleucine-tyrosine-isoleucine. Dihexa was built by protecting and modifying that minimal core so it resists enzymatic breakdown while retaining its ability to engage the HGF/c-Met system.

What is the HGF/c-Met system?

HGF (hepatocyte growth factor) is a signaling protein, and c-Met is its receptor tyrosine kinase. The pathway is studied for its roles in cell survival, tissue organization, and — of particular interest here — neuronal development and synaptic plasticity. Dihexa is investigated specifically because it modulates this system.

Does dihexa activate c-Met directly?

No. Published cell-culture work indicates dihexa binds HGF with high affinity and potentiates HGF's activity at the c-Met receptor, rather than directly switching on the receptor itself. This is described as an allosteric, potentiating action on endogenous signaling rather than uncontrolled kinase activation.

The Bottom Line

Dihexa is a compact case study in how targeted edits to a natural peptide scaffold can buy metabolic stability and redirect activity. Starting from a three-residue core of angiotensin IV, chemists capped both ends, traded a half-life of minutes for one of hours, and produced a brain-penetrant molecule that — in cell-culture and animal-model research — potentiates rather than hijacks the HGF/c-Met system. Set beside norleual, its mirror-image inhibitor, dihexa shows just how much a single scaffold can teach about growth-factor modulator design. For further reading, our pieces on allosteric versus orthosteric binding and half-life engineering fill in useful background — always within a research-use-only context.

For research use only. Not for human or animal consumption of any kind. The information in this article is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The statements made have not been evaluated by the U.S. Food and Drug Administration. These products are NOT FDA APPROVED. Please consult with a licensed healthcare professional before making any decisions regarding your health or research.

Optides LLC is a chemical supplier. Optides LLC is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Optides LLC is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act.